然而，这一疗法并非十全十美，它伴随着如影随形的副作用，细胞因子释放综合征（CRS，Cytokine Release Syndrome）和免疫效应细胞相关神经毒性综合征（ICANS，immune effector cell-associated neurotoxicity syndrome）便是其中最为棘手的问题。 CRS 较为常见，患者往往会出现发热 ...

A review of the side effects of CAR T-cell therapy, including CRS, ICANS, tumor lysis syndrome, and late-onset toxicities, and management strategies.

这些毒性包括细胞因子释放综合征（CRS）、神经毒性（也称为免疫效应细胞相关神经毒性综合征，ICANS）、血细胞减少和感染等，成为了限制其广泛应用的主要障碍。例如，CRS 可能引发全身炎症反应，从轻微的流感样症状到严重的低血压、多系统器官衰竭 ...

Bispecific antibodies have become component in the arsenal of treatments for hematologic malignancies; management of their side effects is crucial to their success.

Treatment with siltuximab following CAR-T reduced severity of CRS and ICANS. A phase 2 prospective study is under way to evaluate the agent’s benefit. Siltuximab effectively treated patients who ...

Stifel analyst Benjamin Burnett lowered the firm’s price target on Cabaletta Bio (CABA) to $13 from $26 and keeps a Buy rating on the shares.

It has shown successful results in treating blood cancers but comes with serious risks, including immune effector cell-associated neurotoxicity syndrome (ICANS), which causes inflammation in the ...

ICANS can present with mild symptoms, such as headache or lethargy, but in more severe cases it can be life-threatening, with patients experiencing impaired consciousness, seizures or bleeding in ...

Researchers proposed changing the recommendations for universal driving restrictions after CAR T-cell infusion.